Desotop Gel 0.05%

ডেসোটপ জেল (ডেসোনাইড) হলো ০.০৫% শক্তির একটি টপিক্যাল কর্টিকোস্টেরয়েড, যা এসিআই লিমিটেড দ্বারা প্রস্তুত। প্রতি ইউনিটের মূল্য ৳৫০.৩৪। এটি ৩ মাস বা তার বেশি বয়সী রোগীদের হালকা থেকে মাঝারি এটোপিক ডার্মাটাইটিসের চিকিৎসায় ব্যবহৃত হয়। আলো ও আর্দ্রতা থেকে দূরে, ৩০°C তাপমাত্রার নিচে সংরক্ষণ করুন।

Desonide gel is for external use only. Gel should be applied as a thin layer to the affected areas two times daily and rubbed in gently. Therapy should be discontinued when control is achieved. If no improvement is seen within 4 weeks, treatment should be discontinued and Desonide gel should not be used with occlusive dressings.

Pediatric use: The safety and effectiveness of Desonide gel in pediatric patients less than 3 months of age have not been evaluated, and therefore its use in this age group is not recommended.

The most common local side effects are burning, rash and pruritus at the application site. The following additional local side effects have been reported infrequently with topical corticosteroids. They may occur more frequently with the use of occlusive dressings, especially with higher potency corticosteroids: folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, secondary infection, skin atrophy, striae, and miliaria.

Pregnancy Category C. There are no adequate and well-controlled studies in pregnant women. Therefore, Desonide gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in human milk. Caution should be exercised when Desonide gel is administered to a nursing woman.

Desotop gel is to be used as directed by the physician. It is for external use only and avoid contact with the eyes. It should not be used on the underarm or groin areas of pediatric patients. If irritation develops, Desotop gel should be discontinued and appropriate therapy instituted. Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment. If a favorable response does not occur promptly, use of Desotop gel should be discontinued until the infection has been adequately controlled.

Topically applied Desotop gel can be absorbed in sufficient amounts to produce systemic effects.